JP2021512159A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021512159A5 JP2021512159A5 JP2020561952A JP2020561952A JP2021512159A5 JP 2021512159 A5 JP2021512159 A5 JP 2021512159A5 JP 2020561952 A JP2020561952 A JP 2020561952A JP 2020561952 A JP2020561952 A JP 2020561952A JP 2021512159 A5 JP2021512159 A5 JP 2021512159A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fragment
- sequence
- fusion protein
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 26
- 108020001507 fusion proteins Proteins 0.000 claims 16
- 102000037865 fusion proteins Human genes 0.000 claims 16
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 12
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 10
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 7
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 4
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 4
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 3
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000008499 blood brain barrier function Effects 0.000 claims 3
- 210000001218 blood-brain barrier Anatomy 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 230000008827 biological function Effects 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023094278A JP2023123535A (ja) | 2017-01-30 | 2023-06-07 | 血液脳関門移動化合物及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452015P | 2017-01-30 | 2017-01-30 | |
| US201762530980P | 2017-07-11 | 2017-07-11 | |
| IBPCT/IB2018/050576 | 2018-01-30 | ||
| PCT/IB2018/050576 WO2018138709A1 (en) | 2017-01-30 | 2018-01-30 | Blood-brain barrier transmigrating compounds and uses thereof |
| PCT/IB2018/055747 WO2019150183A1 (en) | 2017-01-30 | 2018-07-31 | Blood-brain barrier transmigrating compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023094278A Division JP2023123535A (ja) | 2017-01-30 | 2023-06-07 | 血液脳関門移動化合物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512159A JP2021512159A (ja) | 2021-05-13 |
| JP2021512159A5 true JP2021512159A5 (enExample) | 2021-09-09 |
| JP7458327B2 JP7458327B2 (ja) | 2024-03-29 |
Family
ID=62977950
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541280A Active JP7449092B2 (ja) | 2017-01-30 | 2018-01-30 | 血液脳関門移動化合物及びその使用 |
| JP2020561952A Active JP7458327B2 (ja) | 2017-01-30 | 2018-07-31 | 血液脳関門移動化合物及びその使用 |
| JP2023094278A Pending JP2023123535A (ja) | 2017-01-30 | 2023-06-07 | 血液脳関門移動化合物及びその使用 |
| JP2024031648A Pending JP2024081644A (ja) | 2017-01-30 | 2024-03-01 | 血液脳関門移動化合物及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541280A Active JP7449092B2 (ja) | 2017-01-30 | 2018-01-30 | 血液脳関門移動化合物及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023094278A Pending JP2023123535A (ja) | 2017-01-30 | 2023-06-07 | 血液脳関門移動化合物及びその使用 |
| JP2024031648A Pending JP2024081644A (ja) | 2017-01-30 | 2024-03-01 | 血液脳関門移動化合物及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11702466B2 (enExample) |
| EP (2) | EP3574002A4 (enExample) |
| JP (4) | JP7449092B2 (enExample) |
| KR (3) | KR102676279B1 (enExample) |
| CN (2) | CN110382522B (enExample) |
| AU (4) | AU2018212860A1 (enExample) |
| CA (2) | CA3052058A1 (enExample) |
| WO (2) | WO2018138709A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7449092B2 (ja) | 2017-01-30 | 2024-03-13 | ナショナル リサーチ カウンシル オブ カナダ | 血液脳関門移動化合物及びその使用 |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| MA54070A (fr) * | 2018-10-29 | 2021-09-08 | Biogen Ma Inc | Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| WO2021097360A1 (en) | 2019-11-15 | 2021-05-20 | University Of Tennessee Research Foundation | Modified immunoglobulins for targeting amyloid deposits |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| US20240216556A1 (en) * | 2021-05-05 | 2024-07-04 | University Of Tennessee Research Foundation | Peptide-fc fusions for treating amyloid disorders |
| WO2022246433A1 (en) | 2021-05-18 | 2022-11-24 | University Of Tennessee Research Foundation | Antibody-peptide fusion proteins for treating amyloid disorders |
| KR102475326B1 (ko) * | 2022-01-27 | 2022-12-07 | 한국기초과학지원연구원 | 신규한 펩타이드 유사체 및 이를 포함하는 알츠하이머 병 예방 조성물 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5385915A (en) | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
| US5874239A (en) | 1993-07-30 | 1999-02-23 | Affymax Technologies N.V. | Biotinylation of proteins |
| AU2001263006A1 (en) | 2000-05-18 | 2001-11-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US20030190598A1 (en) * | 2000-05-26 | 2003-10-09 | Jasmid Tanha | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| CA2441903C (en) * | 2000-05-26 | 2012-07-31 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| AU2002304814A1 (en) | 2001-03-14 | 2002-11-05 | Hybrigenics | Protein-protein interactions in adipocytes |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| JP2003135075A (ja) * | 2001-11-05 | 2003-05-13 | Research Association For Biotechnology | 新規な全長ｃＤＮＡ |
| CA2468583C (en) | 2001-11-30 | 2012-05-01 | C. Roger Mackenzie | Self-assembling multimeric binding complexes derived from ab5 toxin family members |
| EP1452601A1 (en) | 2003-02-28 | 2004-09-01 | Roche Diagnostics GmbH | Enhanced expression of fusion polypeptides with a biotinylation tag |
| CA2562833A1 (en) * | 2004-04-27 | 2005-11-03 | Galapagos N.V. | Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts |
| ATE439443T1 (de) * | 2005-06-17 | 2009-08-15 | Ca Nat Research Council | NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON |
| EP1943341A4 (en) | 2005-09-27 | 2010-07-07 | Ca Nat Research Council | BLOOD-BRAIN-SPEED-EPITOPES AND USES THEREOF |
| TW200907056A (en) * | 2007-03-28 | 2009-02-16 | Astrazeneca Ab | New method |
| EP2558503B1 (en) | 2010-04-14 | 2015-12-09 | National Research Council of Canada | Compositions and methods for brain delivery of analgesic peptides |
| US20110269735A1 (en) * | 2010-04-19 | 2011-11-03 | Celera Corporation | Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof |
| ES2664989T3 (es) | 2010-10-01 | 2018-04-24 | National Research Council Of Canada | Anticuerpos ANTI-CEACAM6 y usos de los mismos |
| CN104159922B (zh) * | 2012-01-10 | 2018-03-02 | 比奥根Ma公司 | 对转运治疗性分子穿过血脑屏障的增强 |
| MX367126B (es) * | 2012-08-29 | 2019-08-06 | Hoffmann La Roche | Transporte para atravesar la barrera hematoencefálica. |
| EA035517B1 (ru) * | 2014-03-06 | 2020-06-29 | Нэшнл Рисеч Каунсил Оф Канада | Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения |
| JP6541237B2 (ja) | 2014-03-06 | 2019-07-10 | ナショナル リサーチ カウンシル オブ カナダ | インスリン様成長因子１受容体特異的抗体及びそれらの使用 |
| EP3114142B1 (en) * | 2014-03-06 | 2019-06-05 | National Research Council of Canada | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
| EP3233922B1 (en) | 2014-12-19 | 2022-05-11 | MedImmune Limited | Blood brain barrier transport molecules and uses thereof |
| US20200231652A1 (en) | 2015-08-31 | 2020-07-23 | National Research Council Of Canada | Tgf-b-receptor ectodomain fusion molecules and uses thereof |
| MX389765B (es) * | 2016-07-06 | 2025-03-20 | Nat Res Council Canada | Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos. |
| US10906973B2 (en) * | 2016-12-12 | 2021-02-02 | National Research Council Of Canada | Antibody variants transmigrating the blood-brain barrier and uses thereof |
| JP7449092B2 (ja) | 2017-01-30 | 2024-03-13 | ナショナル リサーチ カウンシル オブ カナダ | 血液脳関門移動化合物及びその使用 |
-
2018
- 2018-01-30 JP JP2019541280A patent/JP7449092B2/ja active Active
- 2018-01-30 KR KR1020197025302A patent/KR102676279B1/ko active Active
- 2018-01-30 AU AU2018212860A patent/AU2018212860A1/en not_active Abandoned
- 2018-01-30 WO PCT/IB2018/050576 patent/WO2018138709A1/en not_active Ceased
- 2018-01-30 CN CN201880015949.5A patent/CN110382522B/zh active Active
- 2018-01-30 CA CA3052058A patent/CA3052058A1/en active Pending
- 2018-01-30 KR KR1020247019801A patent/KR20240095466A/ko active Pending
- 2018-01-30 EP EP18745446.7A patent/EP3574002A4/en active Pending
- 2018-01-30 US US16/481,898 patent/US11702466B2/en active Active
- 2018-07-31 WO PCT/IB2018/055747 patent/WO2019150183A1/en not_active Ceased
- 2018-07-31 CN CN201880091218.9A patent/CN111886240A/zh active Pending
- 2018-07-31 US US16/965,885 patent/US20230257424A1/en not_active Abandoned
- 2018-07-31 EP EP18904229.4A patent/EP3746460A4/en not_active Withdrawn
- 2018-07-31 CA CA3089816A patent/CA3089816A1/en active Pending
- 2018-07-31 JP JP2020561952A patent/JP7458327B2/ja active Active
- 2018-07-31 KR KR1020207025008A patent/KR20200116143A/ko not_active Ceased
- 2018-07-31 AU AU2018405992A patent/AU2018405992A1/en not_active Abandoned
-
2022
- 2022-03-23 AU AU2022202015A patent/AU2022202015B2/en active Active
-
2023
- 2023-03-14 US US18/183,812 patent/US20230279088A1/en not_active Abandoned
- 2023-06-07 JP JP2023094278A patent/JP2023123535A/ja active Pending
-
2024
- 2024-03-01 JP JP2024031648A patent/JP2024081644A/ja active Pending
- 2024-03-20 AU AU2024201813A patent/AU2024201813A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240076370A1 (en) | Antibodies targeting g-protein coupled receptor and methods of use | |
| US12343401B2 (en) | Modular self assembly disassembly (SADA) technologies | |
| CN112646031B (zh) | 抗4-1bb纳米抗体及其用途 | |
| US10899835B2 (en) | IgM Fc and J-chain mutations that affect IgM serum half-life | |
| KR102501921B1 (ko) | 유도성 결합 단백질 및 사용 방법 | |
| RU2558301C2 (ru) | Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие | |
| RU2663349C2 (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| JP5911821B2 (ja) | 受容体チロシンキナーゼａｌｋの細胞外ドメインに結合する抗体 | |
| KR20190134997A (ko) | 항-tau 항체 및 이의 사용 방법 | |
| JP2017529067A (ja) | Ｃｄ３結合ドメイン | |
| JP2020124203A (ja) | 血液脳関門輸送分子およびそれらの使用 | |
| JP2017537082A5 (enExample) | ||
| JP2022532370A5 (enExample) | ||
| JP2023544211A5 (enExample) | ||
| KR20230104229A (ko) | Cd3에 결합하는 폴리펩티드 구축물 | |
| KR20230098335A (ko) | 클리핑 비율이 감소된 항원 결합 도메인 | |
| JP2024535851A5 (enExample) | ||
| CA3160855A1 (en) | Antibodies targeting cell surface deposited complement protein c3d and use thereof | |
| HK40122548A (en) | Anti-cd44v6 antibodies and their use to treat cd44v6 overexpressing cancers | |
| EP2319871A1 (en) | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same | |
| EP2308896A1 (en) | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |